journal article·2023-08-14

Molecular Mechanism Underlying the Action of a Celastrol-Loaded Layered Double Hydroxide-Coated Magnesium Alloy in Osteosarcoma Inhibition and Bone Regeneration

Shi Cheng, Hongwei Shao, Dong Yin, Jielong Zhou, Linjia Jian, Juning Xie, Yu Zhang, Donghui Wang, Feng Peng

Publisher page

Abstract

Osteosarcoma (OS) is a malignant bone tumor that threatens human health. Surgical removal of the tumor and followed by implantation with a graft is the golden standard for its clinical treatment. However, avoiding recurrence by enhancing the antitumor properties of the implants and improving osteogenesis around the implants remain a challenge. Here, we developed a layered double hydroxide (LDH)-coated magnesium (Mg) alloy and loaded it with celastrol. The celastrol-loaded Mg alloy exhibited enhanced corrosion resistance and sustained release of celastrol. In vitro cell culture suggested that the modified Mg alloy loaded with an appropriate amount of celastrol significantly inhibited the proliferation and migration of bone tumor cells while having little influence on normal cells. A mechanistic study revealed that the celastrol-loaded Mg alloy upregulated reactive oxygen species (ROS) generation in bone tumor cells, resulting in mitochondrial dysfunction due to reduced membrane potential, thereby inducing bone tumor cell apoptosis. Furthermore, it was found that celastrol-induced autophagy in tumor cells inhibited cell apoptosis in the initial 6 h. After ≥12 h of culture, inhibition of the PI3K-Akt-mTOR signaling pathway was noted, resulting in excessive autophagy in tumor cells, finally causing cell apoptosis. The celatsrol-loaded Mg alloy also exhibited effective antitumor properties in a subcutaneous tumor model. In vitro tartrate-resistant acid phosphatase (TRAP) staining and gene expression results revealed that the modified Mg alloy reduced the viability of osteoclasts, inducing a potential pathway for the increased bone regeneration around the modified Mg alloy seen in vivo . Together, the results of our study show that the celatsrol-loaded Mg alloy might be a promising implant for treating OS.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Orthopaedic implants and arthroplasty · Magnesium Alloys: Properties and Applications · Bone Tissue Engineering Materials

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Medical Research Institute, Department of Orthopedics, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China

GuangDong Engineering Technology Research Center of Functional Repair of Bone Defects and Biomaterials, Guangzhou 510080, China

School of Health Science and Biomedical Engineering, Hebei University of Technology, Tianjin 300130, China

Funding

National Natural Science Foundation of China · Natural Science Foundation of Guangdong Province · Guangdong Provincial People's Hospital · Medical Research Fund Project of Guangdong

References (51)

Show source-provided references
1. 10.1016/j.ctrv.2006.05.00510.1016/j.ctrv.2006.05.005 ↗
2. 10.1093/annonc/mdq27610.1093/annonc/mdq276 ↗
3. 10.1016/j.knee.2021.10.01410.1016/j.knee.2021.10.014 ↗
4. 10.1038/s41598-021-98442-610.1038/s41598-021-98442-6 ↗
5. 10.3390/ph1409092310.3390/ph14090923 ↗
6. 10.1016/j.ctrv.2013.11.00610.1016/j.ctrv.2013.11.006 ↗
7. 10.1111/bph.1571310.1111/bph.15713 ↗
8. 10.1016/j.jtcvs.2020.10.13710.1016/j.jtcvs.2020.10.137 ↗
9. Zhu W. G. · J. Buon · 2019 · 24 · 1181
10. 10.3389/fonc.2021.75892110.3389/fonc.2021.758921 ↗
11. 10.1038/s41571-021-00519-810.1038/s41571-021-00519-8 ↗
12. 10.1016/j.pmatsci.2008.06.00410.1016/j.pmatsci.2008.06.004 ↗
13. 10.2320/matertrans.46.161010.2320/matertrans.46.1610 ↗
14. 10.1016/j.actbio.2012.06.03710.1016/j.actbio.2012.06.037 ↗
15. Lah N. A. C. · Pertanika J. Sci. Technol. · 2019 · 27 · 459
16. 10.7150/ntno.5640110.7150/ntno.56401 ↗
17. 10.1016/j.jbiomech.2014.12.02110.1016/j.jbiomech.2014.12.021 ↗
18. 10.1016/j.bioactmat.2021.02.03210.1016/j.bioactmat.2021.02.032 ↗
19. 10.1016/j.bioactmat.2021.04.01210.1016/j.bioactmat.2021.04.012 ↗
20. 10.1016/j.actbio.2021.06.00410.1016/j.actbio.2021.06.004 ↗
21. 10.1016/j.actbio.2021.04.05110.1016/j.actbio.2021.04.051 ↗
22. 10.1007/s40843-020-1509-210.1007/s40843-020-1509-2 ↗
23. 10.1021/acsbiomaterials.1c0028810.1021/acsbiomaterials.1c00288 ↗
24. 10.1016/j.jallcom.2020.15701010.1016/j.jallcom.2020.157010 ↗
25. 10.1016/j.actbio.2018.02.02310.1016/j.actbio.2018.02.023 ↗
26. 10.1073/pnas.151823811310.1073/pnas.1518238113 ↗
27. 10.1016/j.jma.2019.09.00810.1016/j.jma.2019.09.008 ↗
28. 10.1021/acsami.6b1297410.1021/acsami.6b12974 ↗
29. 10.1016/j.bioactmat.2020.07.01410.1016/j.bioactmat.2020.07.014 ↗
30. 10.1021/acsomega.1c0316910.1021/acsomega.1c03169 ↗
31. 10.1016/j.cell.2007.08.02110.1016/j.cell.2007.08.021 ↗
32. 10.1161/CIRCRESAHA.119.31586110.1161/CIRCRESAHA.119.315861 ↗
33. 10.1039/D0TB01939A10.1039/D0TB01939A ↗
34. 10.1007/s11101-021-09785-x10.1007/s11101-021-09785-x ↗
35. 10.3389/fphar.2020.55874110.3389/fphar.2020.558741 ↗
36. 10.1186/s13046-019-1173-410.1186/s13046-019-1173-4 ↗
37. 10.3389/fphar.2018.0010410.3389/fphar.2018.00104 ↗
38. 10.1039/D1BM01075A10.1039/D1BM01075A ↗
39. 10.1038/sj.onc.120861510.1038/sj.onc.1208615 ↗
40. 10.1038/cddis.2012.17110.1038/cddis.2012.171 ↗
41. 10.1038/nrd400210.1038/nrd4002 ↗
42. 10.1016/j.semcancer.2020.05.01510.1016/j.semcancer.2020.05.015 ↗
43. 10.1038/s41586-020-1992-710.1038/s41586-020-1992-7 ↗
44. 10.1161/CIRCRESAHA.119.31600710.1161/CIRCRESAHA.119.316007 ↗
45. 10.1038/nrclinonc.2011.7110.1038/nrclinonc.2011.71 ↗
46. 10.7150/thno.4672810.7150/thno.46728 ↗
47. 10.1083/jcb.139.5.128110.1083/jcb.139.5.1281 ↗
48. 10.1038/s41580-019-0173-810.1038/s41580-019-0173-8 ↗
49. 10.1038/sj.cdd.440047610.1038/sj.cdd.4400476 ↗
50. 10.1096/fj.10-16409510.1096/fj.10-164095 ↗
51. 10.1074/jbc.M112.35681610.1074/jbc.M112.356816 ↗